Nicotinic acid and laropiprant

Key facts

Active substance
  • nicotinic acid
  • laropiprant
Therapeutic area
Endocrinology, -gynacology-fertility-metabolism
Decision number
P/45/2007
PIP number
Nicotinic acid and laropiprant
Pharmaceutical form(s)
Prolonged-release tablet
Condition(s) / indication(s)
  • Heterozygous Familial Hypercholesterolaemia
  • Homozygous Familial Hypercholesterolaemia
Route(s) of administration
Oral use
Contact for public enquiries
Merck Sharp and Dohme (Europe), Inc.
Belgium
Tel. +33 180464738
E-mail: pip.information@merck.com
Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

Topics

How useful was this page?

Add your rating